Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-12-02T23:54:55.805Z Has data issue: false hasContentIssue false

EPA-1149 – Assessment of Negative and Affective Symptoms in a Group of Women with Schizophrenia who are in Treatment with Paliperidone Long Acting Injection

Published online by Cambridge University Press:  15 April 2020

A. Döll
Affiliation:
Psychiatry in Infanta Leonor Hospital, Vallecas Villa Mental Health Centre, Alcala de Henares, Spain
R. Moreno
Affiliation:
Psychiatry in Infanta Leonor Hospital, Vallecas Villa Mental Health Centre, Alcala de Henares, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives:

Evaluate the psychopathological changes in a group of women who suffer schizophrenia, before and after beginning treatment with paliperidone long acting injection. We focus on affective and negative symptons.

Material and Method:

We recruit the women from Vallecas Villa Mental Health Centre who initiate paliperidone long acting injection, from 1st of January of 2013. We use for the assessment: Positive and Negative Syndrome Scale (PANSS), Hamilton Depression Rating Scales (HDRS), Clinical Global Impression-Schizophrenia (CG-ISCH), Global Assessment Scale (GAF), Subjective Wellbeing under Neuroleptics (SWN-K) before beginning the treatment and 2 months later.

Results:

Our sample was formed by 20 women, only one left the treatment for secondary effects. In baseline all women were severely ill to moderate ill in Clinical Global Impression Scale. The results in baseline and two months after treatment can be read in table 1. The patients improve in all the scales: in GAF scale the functionality of the patients change from 48 to 62. This recovery seems related with the improvement in affective and negative symptoms, but not with positive symptoms (in fact in baseline mild-moderate).

Conclusions:

Schizophrenia is more than positive symptoms, sometimes the lack of functionality is related with other group of symptoms that initially are considered secondary: affective and negative.

TABLE 1BaselineAfter
AGEA40,23 (9,4) 
PANSS-P21,92 (8,9)13,84 (5,9)
PANSS-N25,23 (8,1)18,76 (6,5)
PANSS-PG 50(10,5)36,53 (12,26)
PANSS-Total97,15 (20,02)69,15 (22,13)
EAAG48,07 (11,99)62,3 (10,53)
HAMILTON18,15 (6,3)10,38 (8,3)
SWN-K58,76 (11,27)74,15 (18,14)

Type
P37 - Women, Gender and Mental Health
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.